Driven by Innovation
Lilly Japan’s Simone Thomsen reflects on six years of leading with purpose and ACCJ collaboration.
When Simone Thomsen arrived in Kobe in 2019 to guide Eli Lilly Japan K.K. as president, she fulfilled one of her longtime career goals. Over the past six years, she has been a critical player in the mission of the American Chamber of Commerce in Japan (ACCJ), serving on the Board of Governors, helping launch the Healthcare x Digital (HxD) initiative, and mentoring young professionals. The ACCJ Journal talked to the 23-year Lilly veteran about her experiences in Japan, the value that ACCJ programs provide, and the mission of the President’s Circle company.
Has leading Lilly Japan been what you expected?
It’s been an amazing journey. The number of medical innovations we have brought to Japanese patients is really impressive. I always knew we had a very strong pipeline, but working with the team here has been impressive for me.
Between 2020 and 2024, we launched 11 new products and received 15 new indications for diabetes, oncology, immunology, Alzheimer's disease, and migraine.
Dealing with three years of Covid-19 was not in my plan, but it was important and interesting.
In January 2023, I became the first female chair of the Japan-Based Executive Committee (JBEC) of the Pharmaceutical Research and Manufacturers of America (PhRMA). That was a new experience for me. There’s a lot going on in the healthcare system and policy, which I have worked on with the PhRMA president, JBEC, and other companies.
Did I envision all that in 2019? No. Looking back at that time, I’m proud of what we have done to support Japanese patients, and how we operate at Lilly Japan as a well-developed organization. The company has grown and matured since then. Our colleagues in Japan would say they’re working for a much better organization today compared with six years ago.
How has the pharmaceutical market changed?
In 2019, Japan was the number two pharmaceutical market globally. Now it ranks sixth. One reason for this shift could be the result of the Japanese government policy decisions in recent years. In the past, the pharmaceutical industry in Japan was viewed as a key growth sector. We are ready to partner with policymakers to try to revitalize the industry while also addressing the challenges brought by a super-aging population.
In the decade since 2016, I have seen many negative ad hoc pricing reforms. I believe there have been
approximately 60 such changes.
We’ve also seen the move from biennial to annual price revisions. What that has done to the industry basically is to accelerate the decline of biopharmaceutical innovation in Japan. Globally, our industry has never been more productive. Every year, we’re investing ¥37 trillion just in R&D. Growth over the past couple of years has been around 99 percent. But in Japan, it has remained relatively stable, having grown only six percent. So, in the area of R&D investment, the gap between what is happening globally and in Japan is pretty striking. And it continues to grow.
Currently, 70 percent of global phase-three trials for any type of medicine are not conducted in Japan. That’s an issue for Japanese patients, because innovative medicines are coming to Japan much later. At a time when you have a super-aging population, you really want to have innovation coming to help you deal with the challenges.
As pharma and as Lilly, of course, we are heavily invested; we want to bring back investment. That’s why, as Lilly Japan and as the JBEC chair, we are in conversation to help the government understand that they need to make positive, bolder reforms.
How has the HxD initiative tied into your goals?
At Lilly, we believe that we can find synergy among medicine, science, and technology. It helps us to serve patients better, to create more engagement and better outcomes. So, we have always been looking at new technology and how it can help us. That’s why HxD was perfect for us and we became one of the founding companies in 2020, along with AstraZeneca and Bayer.
For example, we are focusing on how artificial intelligence (AI) and machine learning can be used to quickly screen millions of molecule options to select the best candidates, allowing us then to accelerate clinical development.
During the pandemic, using these digital technologies allowed us basically to keep all of our clinical development programs going, despite the restrictions. I think that showed us what it could look like and what we actually can accomplish with these tools. It also helped us increase accessibility for patients to enroll in clinical trials. That allowed us to drive diversity—you always want to have a diverse population for the clinical trial design.
We are also utilizing automation for quality control. Specifically, we have automated the visual inspection of our incretin pens, which are used to deliver medications. This technology allows us to increase production with enhanced accuracy and efficiency, thereby meeting the growing demand more effectively.
Tying this back to HxD, when the opportunity arose to collaborate with a few other Kansai-based multinationals with similar interests, we said, why not work with the ACCJ on healthcare digitalization. It’s such a big, important focus area.
How vital is inclusion to Lilly?
We advocate for inclusion because it drives innovation. An inclusive culture empowers employees to bring their unique perspectives and capabilities to work, fostering out-of-the-box thinking. As we are an innovation-based company, this approach remains unchanged.
We started focusing on women’s empowerment 16 or 17 years ago. At the moment, about 30 percent of our leadership roles are held by women, and more than 46 percent of executives are female—the highest number in the industry. Today we also have a strong LGBTQ+ ally network at Lilly Japan. We continue to be recognized as a gold PRIDE company, have participated in the Tokyo Rainbow Pride, and this year we took part in the Osaka and Kobe Rainbow Festas.
We have also been accelerating our accessibility strategy to ensure everyone working at Lilly, regardless of whether they have disabilities, has a seamless experience.
Terminology may shift over time, but our commitment to people will not change. It has been part of our recipe for success. If you work in an inclusive culture and feel welcome, heard, respected, and valued, then you feel a sense of belonging at that company. We’re here to remove barriers, and we will continue to do this for employees as well as the people and communities we serve.
How does the ACCJ factor into your work?
The chamber has facilitated the growth of Lilly Japan. As a President’s Circle member, we participate in the networking and learning opportunities provided by the ACCJ, and our brand visibility has increased.
Personally, I have been proud to serve as an ACCJ–Kansai governor on the Board of Governors. I feel it’s a win-win-win for Lilly Japan, me as a leader, and the ACCJ. By participating, you will have the opportunity to collaborate extensively, provide valuable insights, and influence various areas, particularly in advocacy. For our employees, this serves as an excellent occasion for learning and networking.
I mentioned HxD. ACCJ companies emphasized the importance of healthcare digitalization and proposed collaboration on its design. This initiative would not have been undertaken by Lilly without the involvement of the ACCJ and the opportunity to work with other entities.
We believe that company growth comes from continuous individual development. Networking, discussions, events, and learning offer new ideas that can create business opportunities when brought back to the company.
What advice do you have for women in business?
It starts with identifying your goal and being confident. You need to be passionate about that goal, love what you’re doing, and be good at what you’re doing. But you don’t need to be perfect. That’s a trap women sometimes fall into. Build out a network and use it. You will never succeed if you feel you just need to be excellent to move ahead, because you will hit a certain ceiling. Now, 30-plus years into my career, that’s the recipe I feel has worked for me.
When I started my journey in pharmaceuticals, I wanted to become the first female leader of a purpose-driven multinational company in Japan. Funnily enough, that was my objective. In 2019, I came here and that aspiration came true. So, I hope I’m proof that what I’m saying can work.
